GO:0097707 ferroptosis: Genes, Functions & Methods

Ferroptosis (GO:0097707) is a form of programmed cell death that is mechanistically and morphologically distinct from apoptosis, necroptosis and autophagy. It is defined by the iron-dependent accumulation of lipid peroxidation products and lethal reactive oxygen species (ROS), and it is characterized by smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. Because ferroptosis sits at the intersection of iron metabolism, redox biology and cell death signaling, it has become a major research focus across cancer biology, neuroscience, immunology and cardiovascular medicine. At the molecular level, ferroptosis is controlled by a network of negative and positive regulators. Glutathione peroxidase 4 (GPX4), heat shock protein beta-1 (HSPB1) and nuclear factor erythroid 2-related factor 2 (NRF2) limit ROS production or reduce cellular iron uptake, thereby suppressing ferroptosis. In contrast, NADPH oxidase and p53 promote ferroptosis by increasing ROS production and inhibiting expression of SLC7A11, a specific light-chain subunit of the cystine/glutamate antiporter. This regulatory architecture makes ferroptosis highly amenable to genetic dissection using CRISPR-based models. For researchers, GO:0097707 provides a standardized framework for annotating genes, pathways and experimental phenotypes related to iron-dependent cell death. Understanding its stages, core regulators and disease connections is essential for developing ferroptosis-targeted therapeutics and for interpreting omics and imaging data in the context of this unique cell death modality.

In our own words, ferroptosis (GO:0097707) is a biological process of programmed cell death that is triggered by iron-dependent lipid peroxidation and the accumulation of lethal reactive oxygen species. It is morphologically defined by abnormally small mitochondria with condensed mitochondrial membrane densities, loss or reduction of mitochondrial cristae, and rupture of the outer mitochondrial membrane. Induction involves activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of the cystine/glutamate antiporter. GPX4, HSPB1 and NRF2 function as negative regulators by limiting ROS production and reducing cellular iron uptake, while NADPH oxidase and p53 act as positive regulators by promoting ROS production and inhibiting SLC7A11 expression. Misregulated ferroptosis is implicated in multiple physiological and pathological processes.

Ferroptosis is important because it represents a distinct, genetically encoded cell death pathway that can be therapeutically exploited or blocked depending on disease context. In cancer, inducing ferroptosis offers a strategy to overcome apoptosis resistance, while in cardiovascular and neurodegenerative conditions, inhibiting ferroptosis may protect tissues from iron-dependent injury. Its central role in immunity further highlights its broad physiological relevance.

The following genes and proteins are central to ferroptosis regulation, execution and detection, based on published literature.

Ferroptosis is regulated by a balance between negative regulators such as GPX4, HSPB1 and NRF2, and positive regulators such as NADPH oxidase and p53. The cystine/glutamate antiporter SLC7A11 controls cystine uptake and glutathione synthesis, and its inhibition by p53 promotes ferroptosis. Mitochondrial dynamics regulatory networks crosstalk with ferroptosis, influencing susceptibility. Macrophage-ferroptosis interactions further modulate the process in immune contexts.

Ferroptosis is a novel therapeutic target in cancer because many tumor cells are vulnerable to iron-dependent lipid peroxidation. Inducing ferroptosis can overcome apoptosis resistance, and targeting ferroptosis opens new avenues for novel therapeutics. Macrophage-ferroptosis interactions in the tumor microenvironment also influence tumor progression and therapy response.

Ferroptosis contributes to cardiovascular pathology, including ischemia-reperfusion injury and cardiomyopathy, making it a therapeutic target for cardiovascular disease. Modulating ferroptosis may protect cardiomyocytes from iron-dependent injury.

Ferroptosis plays a role in immunity, influencing immune cell function and inflammatory responses. Interactions between macrophages and ferroptosis are important in host defense and tissue homeostasis.

Iron accumulation and lipid peroxidation link ferroptosis to neurodegenerative processes. Understanding ferroptosis mechanisms may inform neuroprotective strategies.

Ferroptosis detection approaches range from biochemical assays for lipid peroxidation and ROS to morphological imaging of mitochondria. These methods are essential for distinguishing ferroptosis from other cell death modalities.

CRISPR library screening enables genome-wide identification of ferroptosis regulators and therapeutic targets. Functional genomics approaches can uncover novel negative and positive regulators.

Studying crosstalk between ferroptosis and mitochondrial dynamic regulatory networks requires imaging and molecular tools to assess mitochondrial morphology and function.

Investigating ferroptosis in immunity involves co-culture and macrophage-ferroptosis interaction models. These studies reveal how ferroptosis modulates inflammatory responses.

Researchers studying ferroptosis-related genes often need to determine whether a candidate gene is causally involved in iron-dependent cell death, and CRISPR-based models provide the most direct way to test this. By combining knockout, point-mutation, knock-in and overexpression approaches, it is possible to dissect the precise contribution of each gene to ferroptosis initiation, propagation and execution.

Ferroptosis (GO:0097707) is a distinct iron-dependent programmed cell death pathway with unique morphological and biochemical features. Its regulation by GPX4, SLC7A11, HSPB1, NRF2, p53 and NADPH oxidase makes it a rich area for genetic and pharmacological investigation. Ferroptosis is implicated in cancer, cardiovascular disease, immunity and neurodegeneration, offering multiple therapeutic opportunities. CRISPR-based models, including knockout, point-mutation, knock-in and overexpression, are essential for dissecting ferroptosis mechanisms and validating therapeutic targets. EDITGENE provides comprehensive services to support these studies, from cell model generation to library screening and bioinformatics analysis.